Lirafugratinib is an orally bioavailable inhibitor of fibroblast growth factor receptor 2 (FGFR2), designed as a pharmaceutical raw material for research and manufacturing applications. It acts by binding to FGFR2 and inhibiting the downstream signal transduction pathways involved in cellular proliferation.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Lirafugratinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Clindamycin palmitate hydrochloride
pharmaceutical raw material
Alovudine
pharmaceutical raw material
Diflorasone
pharmaceutical raw material
Desmethylflunitrazepam
pharmaceutical raw material
The international HS code for Lirafugratinib (CAS 2549174-42-5) is 2933.59.
2933.59
2933 59 95
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
N-[4-[4-amino-5-[3-fluoro-4-(4-methylpyrimidin-2-yl)oxyphenyl]-7-methylpyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-2-methylprop-2-enamide
XOQVZSSDIQQUGO-UHFFFAOYSA-N
CC1=NC(=NC=C1)OC2=C(C=C(C=C2)C3=C(N(C4=NC=NC(=C34)N)C)C5=CC=C(C=C5)NC(=O)C(=C)C)F
Sourcing Lirafugratinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.